Search

Displaying results 5911 - 5920 of 8697 in total
  1. Drug

    Abacavir hydroxyacetate

    go.drugbank.com/drugs/DB12187
    Investigational

    Prurisol is under investigation for the treatment of Chronic Stable Plaque Psoriasis. Prurisol has been investigated for the treatment of Plaque Psoriasis.

  2. Drug

    FAV-201

    go.drugbank.com/drugs/DB06130
    Experimental

    FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

  3. Drug

    ARC183

    go.drugbank.com/drugs/DB05124
    Experimental

    The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid

  4. Drug

    Oleoyl-estrone

    go.drugbank.com/drugs/DB04870
    Investigational

    Body protein loss is an unpleasant effect of fat loss by the restriction of calories, and studies show that this drug appears to avoid this effect.

  5. Drug

    rGLP-1

    go.drugbank.com/drugs/DB05433
    Experimental

    rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.

  6. Drug

    Pafuramidine

    go.drugbank.com/drugs/DB06532
    Investigational

    Pafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.

  7. Drug

    Phloretin

    go.drugbank.com/drugs/DB07810
    Experimental

    Phloretin is a natural dihydrochalcone found in apples and many other fruits.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A Inhibitors
  8. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).

  9. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. … It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    5-fluorotryptophan

    go.drugbank.com/drugs/DB03314
    Experimental

    5-fluorotryptophan can be used as substrate analogue to study enzyme mechanisms by NMR spectroscopy.